RESUMO
INTRODUCTION: Accurate atrial arrhythmia discrimination is important for dual chamber pacemakers and defibrillators. The aim was to assess the accuracy of atrial arrhythmia recording using modern devices and relate this to atrial tip-to-ring (TTR) distance. METHODS: One hundred eighty-two patients (72 + or - 9 years, 55% male) with paroxysmal atrial fibrillation were enrolled and were included in the study if they had an atrial fibrillation (AF) burden of 1-50% during a monitoring phase. Seventy-nine patients fulfilled these criteria and were followed for at least 5 months. Electrodes were classified as having short (<10 mm), medium (10-12), or long (13-18) atrial TTR spacing. RESULTS: Two thousand eight hundred eighty-three detailed onset reports were analyzed; 730 (25%) demonstrated aberrant sensing. Six percent were due to farfield R wave oversensing (FFRWO) and 19% due to undersensing, sometimes occurring in the same patient and study phase. FFRWO was significantly reduced with short TTR electrodes (P < 0.05). Undersensing due to sensitivity fallout was 18% (short), 24% (medium), and 17% (long) (P = ns). Undersensing due to pacemaker blanking was 11% (short), 11% (medium), and 12% (long) (P = ns). Active fixation electrodes did not show any difference from passive fixation. CONCLUSION: Atrial electrodes with a short TTR (<10 mm) significantly reduce FFRWO without increasing undersensing and should be used routinely in patients with paroxysmal atrial tachyarrhythmias. However, 20% of atrial tachyarrythmia episodes were incorrectly classified as terminated by these modern devices due to undersensing. Clinicians should be wary of using device-derived endpoints that rely on AF episode number or duration as these may be falsely increased or reduced, respectively.
Assuntos
Eletrodos , Marca-Passo Artificial , Taquicardia/diagnóstico , Idoso , Fibrilação Atrial/diagnóstico , Desenho de Equipamento , Feminino , Humanos , Masculino , Sensibilidade e EspecificidadeRESUMO
AIMS: Right ventricular pacing increases the risk of persistent atrial fibrillation (AF) in the long term. The effects of right ventricular pacing on paroxysmal AF (PAF) are unknown. The aim was to examine the effect of right ventricular pacing on AF burden (AFB) in patients with symptomatic drug-resistant PAF. Pooled analysis of pacemaker-derived counters and AF diagnostic data from the Atrial Fibrillation Therapy (AFT) and Pacemaker Atrial Fibrillation Suppression (PAFS) randomized anti-AF pacemaker algorithm trials were used. METHODS AND RESULTS: Five hundred and fifty-four patients from the AFT (n = 372) and PAFS (n = 182) were studied. The individual percentages of pacing, Atrial Sense Ventricular Pace (ASVP), Atrial Pace Ventricular Pace (APVP), and Atrial Pace Ventricular Sense (APVS) as well as total ventricular pacing during synchronous rhythm (VPinSR, %) were examined for an effect on AFB. Three hundred and twenty-one (AFT, age 64 +/- 11, 55% male) and 79 (PAFS, age 71 +/- 8, 54% male) patients had complete data for analysis. Increased VPinSR was weakly associated with an increased AFB (effect size-10% VPinSR increased AFB by only 0.03%) in AFT (P = 0.04) but not PAFS (P = 0.98) or the pooled analysis (P = 0.95). None of the synchronous paced modalities (ASVP, APVP, APVS) significantly increased AFB compared with sinus rhythm (Atrial Sense Ventricular Sense) (P = ns). CONCLUSION: No pacing modality, atrial or ventricular, had a significant effect on AFB. On the basis of these data, the detrimental effect of high-frequency right ventricular pacing on AFB in paced PAF patients, unlike with persistent AF, appears to be minimal in the short term.
Assuntos
Fibrilação Atrial/epidemiologia , Estimulação Cardíaca Artificial/estatística & dados numéricos , Ventrículos do Coração , Disfunção Ventricular Direita/epidemiologia , Disfunção Ventricular Direita/prevenção & controle , Idoso , Comorbidade , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Medição de Risco/métodos , Fatores de Risco , Reino Unido/epidemiologiaRESUMO
AIMS: The PAFS study is a randomized, multicentre investigation of the effects of third generation anti-atrial fibrillation pacemaker algorithms in patients with paroxysmal atrial fibrillation (PAF). METHODS AND RESULTS: 182 patients (72 +/- 9 years, 55% male) with at least three symptomatic episodes of PAF within prior 3 months resistant to two anti-arrhythmics were enrolled. A pacemaker-derived atrial fibrillation (AF) burden of 1-50% was required in the initial induction phase. Seventy-nine patients fulfilled these criteria and were randomized to four, month-long phases in a crossover design. Algorithm phases were 'rate soothing' on, 'ventricular rate stabilization' on, and 'All on', which included these two algorithms plus post-AF response. The algorithm phases were compared to 'All off' dual chamber universal mode (DDD 60) for the analysis. Forty-two percent of patients enrolled in the monitoring phase had no AF. The percentage of AF induced by premature atrial contractions (PACs) was significantly reduced by rate soothing from 25 to 17% (P < 0.05). There was no significant change in AF burden, AF episode number, quality of life, or symptoms with any algorithm (P = ns). CONCLUSION: The rate-soothing algorithm by atrial overdrive pacing reduced PAC-initiated PAF. However, there was no overall change in AF burden, PAF episodes, patient symptoms, or quality of life. Forty-two percent of PAF patients did not show any AF after enrollment, suggesting that bradycardia pacing alone eliminates AF.
Assuntos
Fibrilação Atrial/prevenção & controle , Fibrilação Atrial/terapia , Estimulação Cardíaca Artificial , Átrios do Coração/patologia , Taquicardia Paroxística/prevenção & controle , Taquicardia Paroxística/terapia , Idoso , Algoritmos , Fibrilação Atrial/fisiopatologia , Bradicardia , Estudos Cross-Over , Feminino , Frequência Cardíaca/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Estatísticos , Taquicardia Paroxística/fisiopatologia , Resultado do TratamentoRESUMO
BACKGROUND: Current guidelines for transthoracic direct-current cardioversion (DCCV) of atrial fibrillation (AF) recommend a step-up energy protocol. The aim of this study was to compare such a protocol with a protocol involving a high initial energy shock, anteroposterior paddle position and reversal of shock polarity, on cardioversion efficacy, total energy delivery, use of sedation and patient tolerability. METHODS: 261 patients (mean age 71+/-10 years, 62% male) referred for elective DCCV of persistent AF were enrolled. Patients were randomised to either protocol A: (1) 200 J anteroapical, (2) 360 J anteroapical, (3) 360 J anteroposterior; or protocol B: (1) 360 J anteroapical, (2) 360 J anteroposterior, and (3) 360 J posteroanterior. All procedures were performed under sedation with intravenous diazepam. RESULTS: Protocol B improved shock success rates (protocol A first shock success rate=42%, protocol B=68%, p<0.001; protocol A second shock success rate=72%, protocol B 86%, p=0.006; protocol A third shock success rate=83%, protocol B=92%, p=0.03) and required fewer shocks to achieve sinus rhythm (1.3+/-0.6) compared with protocol A (1.6+/-0.7, p<0.001). There were no differences in cumulative energy used (protocol A 473+/-286 J, protocol B 436+/-273 J, p=0.24) or sedation requirements (protocol A diazepam 22.1+/-9.0 mg, protocol B 21.7+/-8.9 mg, p=0.75). Both protocols were equally well tolerated by patients. CONCLUSION: High initial energy increased success rates and decreased the number of shocks but resulted in similar cumulative energy delivery, sedation use and patient tolerability compared with a conventional step-up protocol.
Assuntos
Fibrilação Atrial/terapia , Cardioversão Elétrica/métodos , Idoso , Protocolos Clínicos , Feminino , Humanos , MasculinoRESUMO
Paroxysmal atrial fibrillation is a common occurrence in patients following thoracic surgery and in some patients remains refractory to medical therapy. New pacemaker devices are available with atrial preventative and termination pacing algorithms designed to reduce arrhythmia recurrences. This report describes the implantation of such a device in a patient following pneumonectomy and the subsequent effect on atrial arrhythmia burden.
Assuntos
Fibrilação Atrial/etiologia , Fibrilação Atrial/terapia , Marca-Passo Artificial , Pneumonectomia/efeitos adversos , Neoplasias Brônquicas/epidemiologia , Neoplasias Brônquicas/cirurgia , Estimulação Cardíaca Artificial/métodos , Comorbidade , Progressão da Doença , Eletrodos Implantados , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva , Fatores de TempoRESUMO
BACKGROUND: The effects of patient-activated atrial defibrillation on subclinical myocardial injury are unknown. Using biochemical markers, this study assessed the effect of a single internal atrial shock delivered by the implantable atrial defibrillator on myocardial damage, neurohormonal activation and inflammation. METHODS: Twelve patients were implanted with a dual chamber defibrillator for the sole indication of drug refractory symptomatic persistent atrial fibrillation (AF). All had maximum defibrillation energy programmed to maximise the first shock success rate. Creatine kinase isoenzyme, troponin T, cortisol, catecholamines, C-reactive protein and brain natriuretic peptide were measured (i) during sinus rhythm, (ii) 8 h after onset of spontaneously occurring AF (before cardioversion) and (iii) 8 h following successful patient activated cardioversion. RESULTS: There was no change in creatine kinase, troponin T, cortisol or C-reactive protein during AF or following internal cardioversion. Brain natriuretic peptide levels rose from a median value of 56 pg/ml during sinus rhythm (inter-quartile range 14-92 pg/ml) to 133 pg/ml during AF (30-262 pg/ml), p=0.002. There was a decrease 8 h after cardioversion to baseline (52 and 40-189 pg/ml), p=0.01. There were increases in serum adrenaline and noradrenaline levels during AF from 0.43 (0.12-0.61) to 0.58 pg/ml (0.39-0.80 pg/ml), p=0.002 and from 2.06 (1.61-2.59) to 2.83 nmol/l (2.43-3.46 nmol/l), p=0.02, respectively. These figures reverted to baseline levels 8 h post-cardioversion. CONCLUSIONS: Internal atrial defibrillation does not result in myocardial injury. The onset of AF results in sympathetic activation and increased brain natriuretic peptide levels, which resolve following restoration of sinus rhythm.
Assuntos
Fibrilação Atrial/terapia , Proteína C-Reativa/metabolismo , Catecolaminas/sangue , Creatina Quinase/sangue , Cardioversão Elétrica/efeitos adversos , Isquemia Miocárdica/sangue , Troponina T/sangue , Adulto , Idoso , Fibrilação Atrial/sangue , Biomarcadores/sangue , Cromatografia Líquida de Alta Pressão , Feminino , Seguimentos , Humanos , Hidrocortisona/sangue , Imunoensaio , Inflamação/sangue , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/etiologia , Peptídeo Natriurético Encefálico/sangue , Nefelometria e Turbidimetria , Índice de Gravidade de DoençaRESUMO
Acceptability of the atrial defibrillator is partly limited by concerns about shock related anxiety and discomfort. Sedation and/or automatic cardioversion therapy during sleep may ease shock discomfort and improve patient acceptability. Three atrial cardioversion techniques were compared: patient-activated cardioversion with sedation, automatic night cardioversion with sedation, and automatic night cardioversion without sedation. Sedation was oral midazolam (15 mg). Fifteen patients aged 60 +/- 13 years were assigned each strategy randomly for three consecutive episodes of persistent atrial fibrillation requiring cardioversion. Patients completed questionnaires for multiple parameters immediately and again at 24 hours postcardioversion. Atrial cardioversion strategies with oral sedation (patient-activated and automatic) significantly reduced shock recall by 77% (P < 0.005), therapy dissatisfaction by 57%-71% (P < 0.03), shock discomfort by 61%-73% (P < 0.01), shock pain by 79%-83% (P < 0.001), and shock intensity by 73%-77% (P < 0.03), compared to automatic night cardioversion without sedation (P < 0.02). Atrial shock pain was short-lived and caused little disruption to the patients' daily routines. Automatic night cardioversion without sedation, resulted in sleep disturbances not seen with the other strategies (42% vs 0%, P < 0.001) as well as concerns about future pain or discomfort. Twelve patients (80%) chose patient-activated cardioversion with sedation as their preferred treatment, and three (20%) remainder chose automatic night cardioversion with sedation. Ninety percent of patients chose automatic night cardioversion without sedation as the least acceptable therapy. Sedation significantly increases atrial shock acceptability regardless of cardioversion method. Shocks without sedation are significantly less acceptable to patients using the atrial defibrillators.
Assuntos
Fibrilação Atrial/terapia , Desfibriladores Implantáveis , Hipnóticos e Sedativos/administração & dosagem , Midazolam/administração & dosagem , Aceitação pelo Paciente de Cuidados de Saúde , Ansiedade/etiologia , Estudos Cross-Over , Desfibriladores Implantáveis/efeitos adversos , Desfibriladores Implantáveis/psicologia , Cardioversão Elétrica/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dor/etiologia , Dor/psicologia , Satisfação do Paciente , Percepção , Transtornos do Sono-Vigília/etiologiaRESUMO
With an aging population, atrial fibrillation is becoming an increasingly common cause of hospital admission. Patients with recurrent, symptomatic persistent atrial fibrillation often require repeated admissions to the hospital for cardioversion. The development of the atrial defibrillator has empowered such patients to take charge of their condition and perform cardioversion on themselves at home. This liberates them from the worry of hospitalization and can increase patient confidence. The implantation of an atrial defibrillator, however, has some disadvantages, and long-term use of the device exposes patients to some of the psychological adaptations that occur in recipients of implantable devices. This article discusses in depth the patient selection process, the implantation procedure, the use of the atrial defibrillator, and problems that can arise during long-term follow-up.
Assuntos
Fibrilação Atrial/terapia , Desfibriladores Implantáveis , Antiarrítmicos/uso terapêutico , Desfibriladores Implantáveis/efeitos adversos , Desfibriladores Implantáveis/psicologia , Cardioversão Elétrica , Desenho de Equipamento , Falha de Equipamento , Humanos , Educação de Pacientes como Assunto , Seleção de Pacientes , Pré-Medicação , Prevenção Secundária , AutocuidadoRESUMO
UNLABELLED: Atrial Defibrillator. INTRODUCTION: The atrial defibrillator empowers patients to cardiovert themselves from atrial arrhythmias at a time that is socially and physically acceptable, thereby preventing hospitalization. The long-term psychosocial effects of repeated use of the patient-activated atrial defibrillator at home are unknown. METHODS AND RESULTS: Eighteen patients underwent placement of the Jewel AF atrial defibrillator for persistent atrial fibrillation only. All patients performed manually activated cardioversions at home under self-administered sedation. Automatic shock therapies were disabled. Hospital Anxiety and Depression Scale and Multidimensional Health Locus of Control questionnaires were obtained before implant. All patients completed questionnaires 1 year after device implant and at long-term follow-up. The spouse or partner of each patient was interviewed to identify positive and negative aspects of manual cardioversion at home. The baseline patient scores for both anxiety (5.7 +/- 2.7) and depression (3.4 +/- 2.3) fell within the predefined range of normality. At 1 year, there was no significant change in anxiety (4.9 +/- 3.7, P = 0.39) or depression (2.4 +/- 1.8, P = 0.06). At long-term follow-up (mean 28 months), a total of 377 patient-activated cardioversions were performed out of hospital (median 15 per patient). Scores for anxiety (6.0 +/- 4.0, P = 0.70) and depression (3.2 +/- 2.5, P = 0.68) remained unchanged. CONCLUSION: During long-term follow-up, patient-activated cardioversion using the atrial defibrillator was not associated with increased anxiety or depression. The procedure was well tolerated by patients and their partners, offering an acceptable treatment option for patients with recurrent persistent atrial fibrillation.